Human Immunology Biosciences Stock

www.hibio.comHealthcare / BioTech & PharmaFounded: 2021

Human Immunology Biosciences, or HI-Bio, is a biotechnology company using human genetic and immunological research. With a mission to develop precise therapies for patients with immune-mediated diseases (IMDs), HI-Bio focuses on draining the cellular drivers of these diseases to grow their programs to other IMD indicators through clinical-stage programming and pipeline. Human Immunology Biosciences was founded by Travis Murdoch in 2021 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Human Immunology Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Human Immunology Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Human Immunology Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Travis Murdoch MD
Founder & Chief Executive Officer
Carl Enell
Chief Operating Officer
Christina Carlson J.D.
General Counsel
Uptal Patel M.D.
Chief Medical Officer
Michele Anderson
Senior Vice President, Regulatory Affairs
Lorna Dean
Senior Vice President, Development Operations

Board Members

Barbara Krebs-Pohl Ph.D.
MorphoSys
Carol Suh
ARCH Venture Partners
Chris Dimitropoulos
Alpha Wave Global
Rachel Mears JD
Jeito
Fred Cohen MD, D.Phil.
Monograph Capital
Paul Berns
ARCH Venture Partners

Frequently Asked Questions About Human Immunology Biosciences’ Stock

plusminus
Can you buy Human Immunology Biosciences’ stock?
Human Immunology Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Human Immunology Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Human Immunology Biosciences’ stock?
Yes, you can sell stock of a private company like Human Immunology Biosciences. Forge can help you sell your Human Immunology Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Human Immunology Biosciences’ stock price?
Human Immunology Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Human Immunology Biosciences’ private market stock price with Forge Data.
plusminus
What is Human Immunology Biosciences’ stock ticker symbol?
Human Immunology Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases
Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.
Updated on: Jun 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.